Idera Pharmaceuticals to Present at Rodman and Renshaw Techvest 7th Annual Healthcare Conference
November 03 2005 - 8:05AM
PR Newswire (US)
CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idera
Pharmaceuticals, Inc. (AMEX:IDP) announced today that Timothy
Sullivan, Ph.D., Vice President of Development Programs, is
scheduled to present an overview of the Company, its product
pipeline, and its technology to investors at the Rodman &
Renshaw Techvest 7th Annual Healthcare Conference, taking place at
The New York Palace Hotel in New York City. The presentation is
scheduled for Monday, November 7, 2005 at 1:00 p.m. ET in the
Kennedy I room. About Idera Pharmaceuticals, Inc. Idera
Pharmaceuticals, Inc. is a biotechnology company focused on the
discovery, development, and commercialization of targeted immune
therapies based on modulation of Toll-like Receptors (TLRs). Idera
has identified novel chemical entities that modulate immune
responses through interactions with TLR9. The Company continues to
identify new drug candidates specific to various diseases,
including cancer, infectious diseases and asthma/allergies, based
on the differentiated biological activities of its proprietary
compounds. The Company's website is located at
http://www.iderapharma.com/. Idera Pharmaceuticals (AMEX:IDP) is
based in Cambridge, Massachusetts. Idera's lead candidate is
IMO-2055, a TLR9 agonist currently in Phase 2 clinical testing for
cancer. Idera is also collaborating with Novartis for the
discovery, development, and commercialization of IMO drug
candidates targeting asthma and allergies. Forward-Looking
Statements This press release contains forward-looking statements
concerning Idera Pharmaceuticals, Inc. that involve a number of
risks and uncertainties. For this purpose, any statements contained
herein that are not statements of historical fact may be deemed to
be forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance through the clinical trial process
on a timely basis or at all and receive approval from the United
States Food and Drug Administration or equivalent foreign
regulatory agencies; whether, if such products receive approval,
they will be successfully distributed and marketed; whether Idera's
cash resources will be sufficient to fund product development and
clinical trials; and such other important factors as are set forth
under the caption "Risk Factors" in Idera's Quarterly Report on
Form 10-Q filed on August 9, 2005, which important factors are
incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements. Contacts:
Idera Pharmaceuticals, Inc. MacDougall Biomedical Communications
617-679-5500 x5517 508-647-0209 x12 Robert G. Andersen Douglas
MacDougall E-mail: E-mail: DATASOURCE: Idera Pharmaceuticals, Inc.
CONTACT: Robert G. Andersen of Idera Pharmaceuticals, Inc.,
+1-617-679- 5500 ext. 5517, ; or Douglas MacDougall of MacDougall
Biomedical Communications, +1-508-647-0209 ext. 12, Web site:
http://www.iderapharma.com/
Copyright
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024